The latest price target for 2seventy bio (NASDAQ:TSVT) was reported by Morgan Stanley on July 29, 2024. The analyst firm set a price target for $6.00 expecting TSVT to rise to within 12 months (a possible 80.72% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for 2seventy bio (NASDAQ:TSVT) was provided by Morgan Stanley, and 2seventy bio maintained their equal-weight rating.

The last upgrade for 2seventy bio Inc happened on January 31, 2024 when Leerink Partners raised their price target to $18. Leerink Partners previously had a market perform for 2seventy bio Inc.

The last downgrade for 2seventy bio Inc happened on January 31, 2024 when TD Cowen changed their price target from N/A to N/A for 2seventy bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 2seventy bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 2seventy bio was filed on July 29, 2024 so you should expect the next rating to be made available sometime around July 29, 2025.

While ratings are subjective and will change, the latest 2seventy bio (TSVT) rating was a maintained with a price target of $7.00 to $6.00. The current price 2seventy bio (TSVT) is trading at is $3.32, which is out of the analyst’s predicted range.